Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Adela, Inc. logo — Advancing the field of epigenomics to transform how cancer i...

Adela, Inc.

Advancing the field of epigenomics to transform how cancer is detected and monitored.

Founded 2020 United States Foster City, United States 70 employees Total: $108.00M Biotechnology, Pharmaceutical

General Information

Company Name Adela, Inc.
Founded Year 2020
Location United States Foster City, United States
Employees 70
Industries Biotechnology, Pharmaceutical
Business Model B2B, B2D, D2C
Revenue Model Service Fee, Usage Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Adela, Inc.. To contact Adela, Inc., visit adelabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Adela, Inc. compare?

A PDF of Adela, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Adela, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Adela, Inc.

Adela, Inc. is poised to revolutionize cancer care through its transformative blood testing technology. With the compelling slogan, "Imagine a world in which a single blood draw can be used to detect and enable early treatment of many different diseases," Adela is committed to leveraging biology to advance cancer diagnostics and treatment.

Founded in 2020, Adela stands at the forefront of innovation in the healthcare sector. The company's unique genome-wide methylation enrichment technology was pioneered by Dr. Daniel De Carvalho at the University Health Network’s Princess Margaret Cancer Centre. Initially, Adela aims to apply this technology across the cancer spectrum—from detection to disease management.

Based in the United States, Adela recently secured a $48.00M Series A investment on September 25, 2023, attracting backing from prominent investors like F-Prime Capital, RA Capital Management, OrbiMed, Decheng Capital, Deerfield Management, and LabCorp. This substantial funding underscores investor confidence in Adela's potential to make significant strides in oncology.

Business keywords: blood-based diagnostics, cancer detection, early disease detection, methylation enrichment technology, genomic analysis, biomarker discovery, precision oncology, liquid biopsy, genome-wide methylome, cancer continuum, health technology, disease management, molecular diagnostics, high-morbidity conditions, cancer care innovation

Services & Products

Developing best-in-class technology for cancer diagnosis through blood tests
Scalable platform for detecting minimal residual disease
Monitoring response in patients receiving immunotherapy
Screening and early detection of multiple types of cancer

Target Customers

Oncologists Cancer treatment centers Healthcare providers Researchers and scientists in oncology Patients undergoing cancer treatment

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC $48.00M 6
F-Prime Capital RA Capital Management OrbiMed
F-Prime Capital, RA Capital Management +4
01 Aug 2023
Series A $60.00M 5
F-Prime Capital RA Capital Management OrbiMed
F-Prime Capital, RA Capital Management +3
01 Jun 2021
Spinout Undisclosed 2
UTEST
UTEST, University Health Network
01 Jan 2020

Adela, Inc. Alternatives & Competitors

View All Alternatives
Adela, Inc. vs
Cosomil, Inc.
Cosomil, Inc. Japan

Developing cutting-edge blood-based diagnostics using our groundbreaking Single Enzyme Activity-base...

Seed
4 employees
Biotechnology, Health Care
Compare Adela, Inc. vs Cosomil, Inc.
Adela, Inc. vs
LCM Genect
LCM Genect Italy

Enable precision medicine

6 employees
Biopharma, Biotechnology
Compare Adela, Inc. vs LCM Genect
Adela, Inc. vs
Foresight Diagnostics (a Natera company)
Foresight Diagnostics (a Natera company) United States

Precision medicine company dedicated to improving the lives of cancer patients through improved canc...

Acquired
112 employees
Biotechnology, Health Care
View all alternatives

FAQ About Adela, Inc.

Advancing the field of epigenomics to transform how cancer is detected and monitored.
Adela, Inc. was founded in 2020.
Adela, Inc. is headquartered in Foster City, United States.
Adela, Inc. operates in Biotechnology and Pharmaceutical. Its work centres on blood-based diagnostics, cancer detection, early disease detection and methylation enrichment technology. Its customers include Oncologists, Cancer treatment centers and Healthcare providers.
Adela, Inc. has a B2B, B2D and D2C business model. Its revenue comes from Service Fee, Usage Based and Licensing.
Adela, Inc. has approximately 70 employees.
Adela, Inc. has completed 3 funding rounds, raising a total of $108.00M.
Adela, Inc. offers: Developing best-in-class technology for cancer diagnosis through blood tests, Scalable platform for detecting minimal residual disease, Monitoring response in patients receiving immunotherapy, Screening and early detection of multiple types of cancer.
Top alternatives and competitors to Adela, Inc. include Cosomil, Inc., LCM Genect, Foresight Diagnostics (a Natera company), Quanterix, Orionis Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Adela, Inc. and Cosomil, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Adela, Inc., https://bouncewatch.com/company/adela-inc, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout